GLP-1/GIP co-agonist – Talk Bio

Actionable Insights Powered by AI

Novo Nordisk’s Pipeline Cull Prompts Hopes of Strategic Shift

1 day ago talkbio0Tagged competition, GLP-1/GIP co-agonist, Leadership Change, Market, Nordisk, Obesity, pipeline cull, R&D pipeline, semaglutide, strategic shift, Wegovy

Novo Nordisk; pipeline cull; GLP-1/GIP co-agonist; obesity drugs; leadership change; strategic shift; semaglutide; Wegovy; R&D pipeline; market competition